Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens

Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality, and the risk of reactivation increases with patients’ age. Bendamustine, an alkylating agent currently used for treatment of indolent and aggr...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Pezzullo Luca, Giudice Valentina, Serio Bianca, Fontana Raffaele, Guariglia Roberto, Martorelli Maria Carmen, Ferrara Idalucia, Mettivier Laura, Bruno Alessandro, Bianco Rosario, Vaccaro Emilia, Pagliano Pasquale, Montuori Nunzia, Filippelli Amelia, Selleri Carmine
Formato:	article
Lenguaje:	EN
Publicado:	De Gruyter 2021
Materias:	cytomegalovirus non-hodgkin lymphoma chemotherapy immunity Medicine R
Acceso en línea:	https://doaj.org/article/5bd5661beda34430babc7d8bcb3163cf
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:5bd5661beda34430babc7d8bcb3163cf
record_format	dspace
spelling	oai:doaj.org-article:5bd5661beda34430babc7d8bcb3163cf2021-12-05T14:10:54ZReal-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens2391-546310.1515/med-2021-0274https://doaj.org/article/5bd5661beda34430babc7d8bcb3163cf2021-04-01T00:00:00Zhttps://doi.org/10.1515/med-2021-0274https://doaj.org/toc/2391-5463Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality, and the risk of reactivation increases with patients’ age. Bendamustine, an alkylating agent currently used for treatment of indolent and aggressive non-Hodgkin lymphomas, can augment the risk of secondary infections including CMV reactivation. In this real-world study, we described an increased incidence of CMV reactivation in older adults (age >60 years old) with newly diagnosed and relapsed/refractory indolent and aggressive diseases treated with bendamustine-containing regimens. In particular, patients who received bendamustine plus rituximab and dexamethasone were at higher risk of CMV reactivation, especially when administered as first-line therapy and after the third course of bendamustine. In addition, patients with CMV reactivation showed a significant depression of circulating CD4+ T cell count and anti-CMV IgG levels during active infection, suggesting an impairment of immune system functions which are not able to properly face viral reactivation. Therefore, a close and early monitoring of clinical and laboratory findings might improve clinical management and outcome of non-Hodgkin lymphoma patients by preventing the development of CMV disease in a subgroup of subjects treated with bendamustine more susceptible to viral reactivation.Pezzullo LucaGiudice ValentinaSerio BiancaFontana RaffaeleGuariglia RobertoMartorelli Maria CarmenFerrara IdaluciaMettivier LauraBruno AlessandroBianco RosarioVaccaro EmiliaPagliano PasqualeMontuori NunziaFilippelli AmeliaSelleri CarmineDe Gruyterarticlecytomegalovirusnon-hodgkin lymphomachemotherapyimmunityMedicineRENOpen Medicine, Vol 16, Iss 1, Pp 672-682 (2021)
institution	DOAJ
collection	DOAJ
language	EN
topic	cytomegalovirus non-hodgkin lymphoma chemotherapy immunity Medicine R
spellingShingle	cytomegalovirus non-hodgkin lymphoma chemotherapy immunity Medicine R Pezzullo Luca Giudice Valentina Serio Bianca Fontana Raffaele Guariglia Roberto Martorelli Maria Carmen Ferrara Idalucia Mettivier Laura Bruno Alessandro Bianco Rosario Vaccaro Emilia Pagliano Pasquale Montuori Nunzia Filippelli Amelia Selleri Carmine Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
description	Cytomegalovirus (CMV) reactivation during chemotherapy or after organ or hematopoietic stem cell transplantation is a major cause of morbidity and mortality, and the risk of reactivation increases with patients’ age. Bendamustine, an alkylating agent currently used for treatment of indolent and aggressive non-Hodgkin lymphomas, can augment the risk of secondary infections including CMV reactivation. In this real-world study, we described an increased incidence of CMV reactivation in older adults (age >60 years old) with newly diagnosed and relapsed/refractory indolent and aggressive diseases treated with bendamustine-containing regimens. In particular, patients who received bendamustine plus rituximab and dexamethasone were at higher risk of CMV reactivation, especially when administered as first-line therapy and after the third course of bendamustine. In addition, patients with CMV reactivation showed a significant depression of circulating CD4+ T cell count and anti-CMV IgG levels during active infection, suggesting an impairment of immune system functions which are not able to properly face viral reactivation. Therefore, a close and early monitoring of clinical and laboratory findings might improve clinical management and outcome of non-Hodgkin lymphoma patients by preventing the development of CMV disease in a subgroup of subjects treated with bendamustine more susceptible to viral reactivation.
format	article
author	Pezzullo Luca Giudice Valentina Serio Bianca Fontana Raffaele Guariglia Roberto Martorelli Maria Carmen Ferrara Idalucia Mettivier Laura Bruno Alessandro Bianco Rosario Vaccaro Emilia Pagliano Pasquale Montuori Nunzia Filippelli Amelia Selleri Carmine
author_facet	Pezzullo Luca Giudice Valentina Serio Bianca Fontana Raffaele Guariglia Roberto Martorelli Maria Carmen Ferrara Idalucia Mettivier Laura Bruno Alessandro Bianco Rosario Vaccaro Emilia Pagliano Pasquale Montuori Nunzia Filippelli Amelia Selleri Carmine
author_sort	Pezzullo Luca
title	Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
title_short	Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
title_full	Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
title_fullStr	Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
title_full_unstemmed	Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens
title_sort	real-world evidence of cytomegalovirus reactivation in non-hodgkin lymphomas treated with bendamustine-containing regimens
publisher	De Gruyter
publishDate	2021
url	https://doaj.org/article/5bd5661beda34430babc7d8bcb3163cf
work_keys_str_mv	AT pezzulloluca realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT giudicevalentina realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT seriobianca realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT fontanaraffaele realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT guarigliaroberto realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT martorellimariacarmen realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT ferraraidalucia realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT mettivierlaura realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT brunoalessandro realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT biancorosario realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT vaccaroemilia realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT paglianopasquale realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT montuorinunzia realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT filippelliamelia realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens AT sellericarmine realworldevidenceofcytomegalovirusreactivationinnonhodgkinlymphomastreatedwithbendamustinecontainingregimens
_version_	1718371606067150848

Real-world evidence of cytomegalovirus reactivation in non-Hodgkin lymphomas treated with bendamustine-containing regimens

Ejemplares similares